Title of article
Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2
Author/Authors
Stuart Cockerill، نويسنده , , Colin Stubberfield، نويسنده , , Jeremy Stables، نويسنده , , J. Malcolm Carter، نويسنده , , Stephen Guntrip، نويسنده , , Kathryn Smith، نويسنده , , Steve McKeown، نويسنده , , Robert Shaw، نويسنده , , Peter Topley، نويسنده , , Lindy Thomsen، نويسنده , , Karen Affleck، نويسنده , , Amanda Jowett، نويسنده , , John David Hayes، نويسنده , , Malcolm Willson، نويسنده , , Patrick Woollard، نويسنده , , David Spalding، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2001
Pages
5
From page
1401
To page
1405
Abstract
Described herein is the design and synthesis of indazolylaminopyridopyrimidines and quinazolines as inhibitors of the class 1 tyrosine kinase receptor family. Data is presented for N4-(1-benzyl-1H-indazol-5-yl)-N6,N6-dimethylpyrido[3,4-d]pyrimidine-4,6-diamine 3B. This compound inhibited EGFr and c-erbB-2 enzymes selectively over other kinases. It inhibited the proliferation of a range of tumour cell lines in vitro and the growth of BT474 xenografts in SCID mice.
Journal title
Bioorganic & Medicinal Chemistry Letters
Serial Year
2001
Journal title
Bioorganic & Medicinal Chemistry Letters
Record number
791419
Link To Document